Literature DB >> 26378640

Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.

Sanjaya K Satapathy1, Arun J Sanyal2.   

Abstract

The epidemic of obesity has resulted in a parallel incremental burden of nonalcoholic fatty liver disease (NAFLD) worldwide. Nonalcoholic fatty liver disease includes a spectrum of liver disease that ranges from simple fat accumulation in the liver to necroinflammation, fibrosis, cirrhosis, and hepatocellular carcinoma, which in essence represent the stages of the natural history of NAFLD. The rising prevalence of NAFLD globally may be accounted for by changes in dietary habits and an increase in sedentary lifestyle. Nonalcoholic steatohepatitis (NASH), the aggressive form of NAFLD, is currently the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. In the current review, the authors discuss the uncertainty around the progression from NAFL (steatosis) to NASH (steatohepatitis), the undisputed progression of NASH to cirrhosis, and the risk factors that predispose to such progression. The published literature on the long-term cardiovascular complications and liver-related mortality of NAFLD is also discussed. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Year:  2015        PMID: 26378640     DOI: 10.1055/s-0035-1562943

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  119 in total

1.  Function of inhibitor of Bruton's tyrosine kinase isoform α (IBTKα) in nonalcoholic steatohepatitis links autophagy and the unfolded protein response.

Authors:  Jeffrey A Willy; Sara K Young; Amber L Mosley; Samer Gawrieh; James L Stevens; Howard C Masuoka; Ronald C Wek
Journal:  J Biol Chem       Date:  2017-07-14       Impact factor: 5.157

Review 2.  Sphingosine kinase and sphingosine-1-phosphate in liver pathobiology.

Authors:  Timothy Rohrbach; Michael Maceyka; Sarah Spiegel
Journal:  Crit Rev Biochem Mol Biol       Date:  2017-06-15       Impact factor: 8.250

3.  Impact of miR-140 Deficiency on Non-Alcoholic Fatty Liver Disease.

Authors:  Benjamin Wolfson; Pang-Kuo Lo; Yuan Yao; Linhao Li; Hongbing Wang; Qun Zhou
Journal:  Mol Nutr Food Res       Date:  2018-06-12       Impact factor: 5.914

4.  Long-Term Follow-Up Study of Liver-Related Outcome After Bilio-Pancreatic Diversion in Patients with Initial, Significant Liver Damage.

Authors:  Edoardo G Giannini; Claudia Coppo; Chiara Romana; Giovanni B Camerini; Franco De Cian; Nicola Scopinaro; Francesco S Papadia
Journal:  Dig Dis Sci       Date:  2018-04-09       Impact factor: 3.199

5.  Liver fibrosis scores predict liver disease mortality in the United States population.

Authors:  Aynur Unalp-Arida; Constance E Ruhl
Journal:  Hepatology       Date:  2017-05-16       Impact factor: 17.425

Review 6.  Liver inflammation and fibrosis.

Authors:  Yukinori Koyama; David A Brenner
Journal:  J Clin Invest       Date:  2017-01-03       Impact factor: 14.808

7.  Pediatric Fatty Liver Disease.

Authors:  Ajay Jain
Journal:  Mo Med       Date:  2019 Mar-Apr

Review 8.  Endocrine-disrupting chemicals and fatty liver disease.

Authors:  Charles E Foulds; Lindsey S Treviño; Brian York; Cheryl L Walker
Journal:  Nat Rev Endocrinol       Date:  2017-05-19       Impact factor: 43.330

Review 9.  The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.

Authors:  Monica D Chow; Yi-Horng Lee; Grace L Guo
Journal:  Mol Aspects Med       Date:  2017-05-05

10.  Diet-Induced Nonalcoholic Fatty Liver Disease Is Associated with Sarcopenia and Decreased Serum Insulin-Like Growth Factor-1.

Authors:  Daniel Cabrera; Alex Ruiz; Claudio Cabello-Verrugio; Enrique Brandan; Lisbell Estrada; Margarita Pizarro; Nancy Solis; Javiera Torres; Francisco Barrera; Marco Arrese
Journal:  Dig Dis Sci       Date:  2016-08-29       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.